Motley Fool1d agobullish
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?The biotech's innovative platform could pay off.
News
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
326last 24h
1831last 7d
326🟢 bullish (7d)
187🔴 bearish (7d)
130publishers
Simply Wall St.7d agobullish
Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?Before you decide whether CRISPR Therapeutics stock looks attractive at around US$52.38, it helps to ask a simple question: what are you actually paying for compared with what the business might be worth? Over the last week the stock return is 0.6%, over the last month it is 5.8%, and over the last year it is 58.0%, while the year-to-date return is a 2.6% decline and the three- and five-year returns are 17.4% and 49.4% declines respectively, which may catch the eye of both momentum fans and...
